About this ETF
The fund, under normal circumstances, invests at least 80% of its assets in the securities that comprise the index or investments with economic characteristics similar to the securities included in the index. The index is provided by S&P Dow Jones Indices LLC (the “index provider”) and is designed to measure the performance of U.S.-listed securities, including depositary receipts, of companies involved in the nanotechnology industry. The fund is non-diversified.
Description from the fund data provider · profile as of Aug 26, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | — | — | — | — | — | +6.19% | — | — | -9.91% |
| Total return | — | — | — | — | — | +6.19% | — | — | -9.91% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Jun 11, 2025. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.65% | Annual cost of a $10,000 investment | $65.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Aug 22, 2026 — portfolio reporting date from the data provider; holdings are not live positions. 30 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | Bruker Biosciences Corp | BRKR | 13.83% | 1.58K | $115.5K |
| 2 | Beam Therapeutics Inc | BEAM | 11.13% | 2.23K | $92.9K |
| 3 | Liquidia Technologies Inc | LQDA | 6.10% | 6.44K | $51.0K |
| 4 | BioNano Genomics Inc | BNGO | 5.37% | 29.30K | $44.8K |
| 5 | Arcturus Therapeutics Holdings Inc | ARCT | 5.24% | 2.43K | $43.7K |
| 6 | ROIVANT SCIENCES LTD | ROIV | 4.65% | 4.45K | $38.9K |
| 7 | NANO DIMENSION LTD USD 1.0 ADR | NNDM | 4.65% | 13.34K | $38.8K |
| 8 | ALKERMES PLC | ALKS | 3.37% | 1.00K | $28.2K |
| 9 | Cabot Corp. | CBT | 3.09% | 324 | $25.8K |
| 10 | LAM RESEARCH | LRCX | 3.06% | 51 | $25.6K |
| 11 | KLA-Tencor Corp. | KLAC | 2.96% | 63 | $24.7K |
| 12 | Thermo Fisher Scientific Inc | TMO | 2.94% | 44 | $24.5K |
| 13 | LUMENTUM HLDGS INC USD 0.001 | LITE | 2.92% | 417 | $24.4K |
| 14 | Alnylam Pharmaceuticals Inc | ALNY | 2.84% | 108 | $23.7K |
| 15 | JAZZ PHARMACEUTICALS PLC USD 0.0001 | JAZZ | 2.79% | 159 | $23.3K |
| 16 | Danaher Corp. | DHR | 2.76% | 90 | $23.0K |
| 17 | IDEX Corp. | IEX | 2.72% | 101 | $22.7K |
| 18 | Moderna Inc | MRNA | 2.66% | 129 | $22.2K |
| 19 | Angiodynamics Inc | ANGO | 2.60% | 1.66K | $21.7K |
| 20 | Vuzix Corp | VUZI | 2.46% | 3.94K | $20.5K |
| 21 | BIONTECH SE | BNTX | 2.39% | 141 | $19.9K |
| 22 | Intellia Therapeutics Inc | NTLA | 2.29% | 480 | $19.1K |
| 23 | META MATERIALS INC | MMAT | 2.02% | 23.00K | $16.8K |
| 24 | PDS BIOTECHNOLOGY CORP | PDSB | 1.99% | 1.92K | $16.6K |
| 25 | SEER INC | SEER | 0.82% | 1.55K | $6.8K |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | — | Paid (last 12 months) | — |
| Frequency | — | SEC yield | Not provided by our data source — see the issuer page |
| Last ex-date | — | Last payment | — |
| Growth 1Y | — | Growth 3Y / 5Y (ann.) | — / — |
No distributions in our database for this fund — it may not pay them, or history has not loaded yet.
Risk Statistics
Liquidity
| Volume today | 172 | Average volume | 172 |
| AUM | $1.3M | Premium/Discount | +0.02% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV — an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source — review them before investing.
Latest News for TYNE
No articles mention this fund directly in the last 7 days — showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.
TYNE